Verastem, Inc. Deferred Income Tax Expense (Benefit)
Verastem, Inc. (VSTM) reported Deferred Income Tax Expense (Benefit) of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-14.
Discontinued › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2023-03-14
- Verastem, Inc. deferred income tax expense (benefit) for fiscal 2022 was $0.00.
- Verastem, Inc. deferred income tax expense (benefit) for fiscal 2021 was $0.00.
- Verastem, Inc. deferred income tax expense (benefit) for fiscal 2020 was $0.00.
- Verastem, Inc. deferred income tax expense (benefit) for fiscal 2019 was $0.00.
| Period end | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-03-14 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-14 |
| 2020-12-31 | $0.00 10-K · filed 2023-03-14 |
| 2019-12-31 | $0.00 10-K · filed 2022-03-28 |
| 2018-12-31 | $0.00 10-K · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 |